ANI Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
ANI Pharmaceuticals has a total shareholder equity of $430.8M and total debt of $625.4M, which brings its debt-to-equity ratio to 145.2%. Its total assets and total liabilities are $1.3B and $856.6M respectively. ANI Pharmaceuticals's EBIT is $21.8M making its interest coverage ratio 1.3. It has cash and short-term investments of $153.3M.
Key information
145.2%
Debt to equity ratio
US$625.36m
Debt
| Interest coverage ratio | 1.3x |
| Cash | US$153.28m |
| Equity | US$430.80m |
| Total liabilities | US$856.58m |
| Total assets | US$1.29b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BSFA's short term assets ($521.3M) exceed its short term liabilities ($189.9M).
Long Term Liabilities: BSFA's short term assets ($521.3M) do not cover its long term liabilities ($666.6M).
Debt to Equity History and Analysis
Debt Level: BSFA's net debt to equity ratio (109.6%) is considered high.
Reducing Debt: BSFA's debt to equity ratio has increased from 91.2% to 145.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BSFA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BSFA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.5% per year.